Language of Resource
Full Text Available
Open Access / OK to Reproduce
We assessed the effects of COVID-19-related changes on take-home methadone dosing in two opioid treatment programs serving five rural Oregon counties.
Take-home methadone dose relaxations were associated with increased methadone take-home doses, improved retention, and decreased UDT opioid positive results among clinically stable patients. Qualitative findings suggest that fewer take-home restrictions are feasible and desirable and do not pose safety or public health harms.